Oncology division

[anonymous]

I hear the Merck deal is becoming unglued!! Not good for Lenvatinib

 

[anonymous]

I hear the Merck deal is becoming unglued!! Not good for Lenvatinib

I heard the same thing. I heard 2 options; 1- buy Lenvima, let all sales people go, because the contract with Eisai is too costly
2- pay Eisai off and walk away from it totally.

Not good news. We need to sty ahead of the curve and look for another place to land.

 

[anonymous]

Just found a way out with better pay and benefits- see you later!!!

 

[anonymous]

Pembro and eribulin combo in phase 1! We goin’ to the moon!!

 

[anonymous]

Most of this will not get approved. the ones that do get approved are small indications. Merck will get tired of this small stuff and move on. They want Lung, Colon, Breast first line therapies not 3rd line or small niche markets.

 

[anonymous]

I hear Merck may take control of our molecule in US leaving Eisai Oncology high and dry. If that happens, did we not think before we purchased a building in NJ!

 

[anonymous]

I hear the same thing. Merck would pay Eisai a royalty which would be the same amount they are making currently without having a marketing, legal, sales or research department expenses in the US on lenvima. Sounds like a smart decision to me.

 

[anonymous]

Alex Scott did the dude.

 

[anonymous]

I hear Merck may take control of our molecule in US leaving Eisai Oncology high and dry. If that happens, did we not think before we purchased a building in NJ!

That’s the problem. None of those overpaid executive wannabe morons think. That place is a shit show. Karma, good ole Karma !!

 

[anonymous]

Also, Paul will be the last person to know. Japan will not tell him anything.
Who runs this place? Not the puppets in NJ.

 

[anonymous]

Why so many openings in the onc division? What is the average base salary offer for these positions?

Eisai’s corporate devotion to oncology in the United States has been weak at best. Most oncologists recognize that it’s just a scavenger—offering “me too” molecules, less than spectacular evidence and nothing special as far as results. Want evidence? Lenvima + anything = crap results. You reap what you sow—and they have nothing but poison ivy seeds.

 

[anonymous]

The alzheimer's fiasco shows we do not follow science. We are in it for the money not the patient, as we so act. Lenvima is our one horse show. What would happen if some bad news came out about it!!!! This place would be a ghost town fast. We hear nothing from upper management, there is no trust and no opportunity for the future. We have nothing coming in the next 5 yrs.

 

[anonymous]

Also, Paul will be the last person to know. Japan will not tell him anything.
Who runs this place? Not the puppets in NJ.

Start looking for a job if you can find anyone to hire you PH, you idiot. And that goes for your henchwomen ! HR clowns included

 

[anonymous]

Are we still in business- No melanoma, talk to you next time we have bad news!

 

[anonymous]

Anyone feel like you are in a car that is lost and, the person driving will not ask for directions? That' how I feel about Eisai's leadership and oncology business.

 

[anonymous]

That is the perfect description! Idiots!

 

[anonymous]

Are these virtual reps going to replace us?

 

[anonymous]

Yup, check out Eisai’s LinkedIn page. They are hiring about 18 MSL’s across the country. I bet they go virtual with reps and have MSLs cover all key accounts. Last year they made the announcements May 21st, so any downsizing will probably be announced around then.

 

[anonymous]

Any word on the National Sales Meeting?

 

[anonymous]

Any word on the National Sales Meeting?

It’s virtual this year from your respective state unemployment offices.